Literature DB >> 364636

Chloroquine treatment in rheumatoid arthritis. Correlation of clinical response to plasma protein changes and chloroquine levels.

F A Wollheim, A Hanson, C B Laurell.   

Abstract

15 patients with active RA were observed over a 3-month period after starting chloroquine treatment. Clinical condition, plasma levels of chloroquine and levels of 15 individual plasma proteins were checked monthly. Nine patients responded favourably to therapy, 6 failed to respond. The responders had lower initial CRP, orosomucoid and ceruloplasmin levels, whereas their IgA and IgM levels were slightly elevated. Significant reductions in the levels of CRP, haptoglobin, orosomucoid, fibrinogen and ceruloplasmin occurred in the responder group of patients. Alfa1-antitrypsin, antichymotrypsin C3 and C4 levels within the normal range were frequently encountered despite other clear-cut signs of activity. The chloroquine levels did not differ between responders and non-responders, the mean concentrations being 1.04 and 1.6 micromol/l respectively. This study has also demonstrated that in selected cases, despite active joint disease, all acute phase proteins may be normal. Finally, it was obvious that chloroquine, even when inducing remission, only brought about a partial normalization of the plasma protein pattern.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 364636     DOI: 10.3109/03009747809095649

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  9 in total

1.  Chloroquine inhibits the intracellular multiplication of Legionella pneumophila by limiting the availability of iron. A potential new mechanism for the therapeutic effect of chloroquine against intracellular pathogens.

Authors:  T F Byrd; M A Horwitz
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

2.  Chloroquine in long-term treatment of rheumatoid arthritis.

Authors:  A Bjelle; A Björnham; A Larsen; T Mjörndal
Journal:  Clin Rheumatol       Date:  1983-12       Impact factor: 2.980

3.  Chloroquine: its effect on leucocyte auto- and heterophagocytosis.

Authors:  C J Jones; M I Jayson
Journal:  Ann Rheum Dis       Date:  1984-04       Impact factor: 19.103

4.  Plasma levels of beta 2-microglobulin in rheumatoid arthritis.

Authors:  K G Sjöblom; T Saxne; F A Wollheim
Journal:  Ann Rheum Dis       Date:  1980-08       Impact factor: 19.103

5.  Chloroquine levels in blood during chronic treatment of patients with rheumatoid arthritis.

Authors:  P Augustijns; P Geusens; N Verbeke
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

6.  Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail.

Authors:  A Adedoyin; R F Frye; K Mauro; R A Branch
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

7.  In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine.

Authors:  Els Keyaerts; Leen Vijgen; Piet Maes; Johan Neyts; Marc Van Ranst
Journal:  Biochem Biophys Res Commun       Date:  2004-10-08       Impact factor: 3.575

8.  Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges.

Authors:  Raymond Chang; Wei-Zen Sun
Journal:  Drug Discov Today       Date:  2020-07-03       Impact factor: 7.851

Review 9.  A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2.

Authors:  Alexander Simonis; Sebastian J Theobald; Gerd Fätkenheuer; Jan Rybniker; Jakob J Malin
Journal:  EMBO Mol Med       Date:  2020-11-03       Impact factor: 12.137

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.